Literature DB >> 6724792

The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study.

T Andersen, P Christoffersen, C Gluud.   

Abstract

Liver morphology and biochemistry were investigated in 61 morbidly obese subjects selected by defined criteria. Median overweight was 82 per cent (range 61 to 170 per cent), and median duration of overweight was 20 years (range two to 45 years). No patient had more than a moderate alcohol consumption and only one was diabetic. Four biopsies (7 per cent) showed normal liver tissue, while fatty change was the main diagnosis in most cases (85 per cent). Increasing degrees of fatty change was significantly (P less than 0.02) associated with presence of lipogranulomas (found in 54 per cent of the biopsies), focal necroses (found in 28 per cent), slight parenchymal inflammation (found in 33 per cent), and Kupffer cell proliferation (found in 49 per cent). Slight portal inflammation was seen in 23 per cent but portal fibrosis in only 2 per cent of the biopsies. No case of cirrhosis was registered. Patients with moderate or severe fatty change, lipogranulomas , focal necroses or with parenchymal inflammation were significantly more obese than patients without these changes (P less than 0.05). Even in absence of fatty change, obese subjects showed a markedly decreased serum albumin concentration and an elevated serum alkaline phosphatase activity (P less than 0.0001) compared with non-obese controls. Serum lactate dehydrogenase and aspartate aminotransferase were significantly raised only in patients with fatty change. With respect to serum bilirubin and plasma cholesterol concentrations no significant differences were detected between patient subgroups and controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6724792

Source DB:  PubMed          Journal:  Int J Obes


  16 in total

1.  Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease.

Authors:  Harminder Singh; Richard Pollock; Julia Uhanova; Meir Kryger; Kim Hawkins; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 2.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 3.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

4.  Pancreatic steatosis: Is it related to either obesity or diabetes mellitus?

Authors:  Raffaele Pezzilli; Lucia Calculli
Journal:  World J Diabetes       Date:  2014-08-15

5.  Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.

Authors:  Metin Basaranoglu; Brent A Neuschwander-Tetri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-04

6.  Assessment of the relationship of hepatic enzymes with obesity and insulin resistance in adults in saudi arabia.

Authors:  Ali Ibrahim Al-Sultan
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

7.  Liver and obesity.

Authors:  F Contaldo; M Mancini; L A Reed
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

8.  Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.

Authors:  Sweta Tandra; Matthew M Yeh; Elizabeth M Brunt; Raj Vuppalanchi; Oscar W Cummings; Aynur Ünalp-Arida; Laura A Wilson; Naga Chalasani
Journal:  J Hepatol       Date:  2010-12-21       Impact factor: 25.083

Review 9.  Pathogenesis and management issues for non-alcoholic fatty liver disease.

Authors:  Marko Duvnjak; Ivan Lerotić; Neven Barsić; Vedran Tomasić; Lucija Virović Jukić; Vedran Velagić
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

Review 10.  From the origin of NASH to the future of metabolic fatty liver disease.

Authors:  Andreas Geier; Dina Tiniakos; Helmut Denk; Michael Trauner
Journal:  Gut       Date:  2021-02-25       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.